For citations:
Menshikova SF, Frolova MA, Glazkova EV, Stenina MB. Ribociclib in the first-line therapy for metastatic hormone-dependent HER2-negative breast cancer in patients with intact ovarian function. Meditsinskiy sovet = Medical Council. 2018;(19):28-30. (In Russ.) https://doi.org/10.21518/2079-701X-2018-19-28-30